KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Assets Average: 2009-2025

Historic Assets Average for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • Acadia Pharmaceuticals' Assets Average rose 35.19% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 35.19%. This contributed to the annual value of $968.4 million for FY2024, which is 44.88% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Assets Average stood at $1.3 billion for Q3 2025, which was up 8.41% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Assets Average peaked at $1.3 billion during Q3 2025, and registered a low of $595.2 million during Q4 2022.
  • Moreover, its 3-year median value for Assets Average was $884.6 million (2024), whereas its average is $902.8 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Assets Average decreased by 16.40% in 2022, and later spiked by 56.69% in 2024.
  • Acadia Pharmaceuticals' Assets Average (Quarterly) stood at $708.9 million in 2021, then dropped by 16.05% to $595.2 million in 2022, then grew by 16.06% to $690.7 million in 2023, then spiked by 56.69% to $1.1 billion in 2024, then skyrocketed by 35.19% to $1.3 billion in 2025.
  • Its Assets Average stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.